

Editor: Sonya Hepinstall +44 207 542 3479 Global Picture Desk: +65 6870 3775 Global Graphics Desk: +65 6870 3595 (All times GMT / ET) Receive this sch...


* Dyax shareholders to get $37.30/shr, plus CVR * Acquisition fuels Shire's rare diseases drug pipeline * CEO insists still has capacity to buy Baxalt...


** Drugmaker Shire's London-listed shares fall to intraday lowest as co says to buy Dyax Corp for c.$5.9 bln to gain access to Dyax's late-stage trea...


(ShareCast News) - Shire has agreed the $5.9bn acquisition of Dyax Corporation, a US-based biotech with a rare-diseases pipeline offering strong growt...


* Drug companies have held early talks, WSJ and FT say * Merger would create world's biggest healthcare group * Pfizer and Allergan decline to comment...